DIA 2021 GLOBAL ANNUAL MEETING VIRTUAL | JUNE 27-JULY 1

Emerging Professional and Student Recommended Sessions

Don't miss these sessions flagged by DIA's Student Advisor as must attend sessions for the emerging professional and student! Visit the **Program Agenda** for details information on these sessions.

Monday | June 28

- 119 SL: FDA Perspectives on Modernization of Clinical Trials: Clinical Practice Data, Decentralized Trials, Digital Health Technologies
- 123 SL: Skills of the Future/The Future of Work
- 128 SL: FDA Science Strategies: Purposeful Scientific Leadership to Advance Innovation and Improve Patient Outcomes
- 133 SL: Role of Clinical Pharmacology Guidances and Policies in Enhancing Drug Development
- 145 SL: Realizing the Value of Digital Biomarkers Across the Product Lifecycle
- 146 SL: Driving Innovation in Data Standards and Regulatory Submissions at FDA
- 149 SL: Culture of Quality: A Competitive Advantage
- 154 SL: How Can We Compliantly Exchange Pre-Approval Information with Payers

Tuesday | June 29

- 214 SL: Developing a Best-in-Class Learning and Performance Program for the MSLs of Today and the Future
- 217 SL: Project Management in Times of Crisis: Perspectives from PMs Supporting COVID-19 Related Projects
- 233 CH L: The Clinical Impact of Medical Information for Healthcare Professionals
- 237 SL: Diversity in Clinical Research: Practical Strategies for Taking Personal Action
- 244 SL: How to Stay Grounded in Project Management Best Practices While Moving at the Speed of Light Integrating a New Company
- 250 SL: How Can Real-World Evidence be Communicated Compliantly to Payers or Healthcare Providers?
- 250.1 RT L: Round Table Discussion: FDA Perspectives on Modernization of Clinical Trials: Clinical Practice Data, Decentralized Trials, Digital Health Technologies
- 251 RT L: Round Table Discussion: Advancing Medicines' Regulation in Europe: Key Strategies to 2025
- 255 SL: Treating Covid-19 Patients with Unproven Interventions Outside Trials: EUAs, Expanded Access, Right to Try, and Off-Label Use
- 258 SL: Effective Medical and Scientific Stakeholder Engagement: Are Digital Solutions The Answer?

- 260 SL: What Do We Do Now? Why You Need A Resource for Ethical Questions During Drug Development
-

Wednesday | June 30

- 305 CH L: Including Data Science in DIA
- 317 SL: Best Practices for Project Managers Working in Drug Development Collaborations
- 323 SL: Collaboration Tools 2021: You Wouldn't Believe What's Available, Much of it for Free!
- 328 NTW: How Can DIA Help You Advance Your Career? Involvement With DIA

Thursday | July 1

- 407 SL: Reliability of Data Results in Clinical Trials (ICH E6 (R2)): What Does it Mean and How Can it be Accomplished?
- 411 SL: Virtual Project Management: A Way Forward!
- 412 SL: Integrated Assessment of US Marketing Applications: A View into FDA Internal Operations
- 414 SL: How to Avoid Shortages? Insights from the EU Executive Steering Group on Shortages – Learnings from the COVID-19 Pandemic
- 428 SL: Mobilizing Manufacturing: Portable and Point of Care Manufacture of Medicines
- 431 L: Managing the Remote World: Concrete Strategies for Productivity and Balance
- 432.2 NTW: Make Connections and Advance Science in DIA Communities
- 439 SL: Preparing Medical Information for Emergency Use Authorization (EUA) to a Full Launch During the COVID-19 Pandemic
- 444 L: Mindfulness: The Power to Be Here, Now
- 445 SL: Career Compass: How do you Find and Define your Career Motivators (s) (True North) in a Transforming / Ever-Changing Workforce
- 446 L: EMA-FDA Question Time
- 447 SL: FDA Town Hall

On Demand Sessions

- 505 OD: Challenges for Medical Information Sharing
- 508 OD: Leveling Up: How Building Your Emotional Intelligence Will Make You an Effective Leader
- 510 OD: If You Have Questions, Contact the Regulatory Project Manager: Best Practices When Interacting with US FDA Regulatory Project Managers
- 511 OD: Global Trends in Regulatory Reliance: Will the COVID-19 Experience Accelerate Implementation?
- 512 OD: Electronic Labeling: Where are we Now and What are the Next Steps in the World?
- 515 OD: Should I be Nice or be Productive? Are These Two Things Mutually Exclusive? Or Can Values and Communication Aid How We Collaborate?
- 522 OD: Gene Therapy Research in Pediatric Populations: Ethical Issues
- 533 OD: Comparing Accelerated Approval Pathways Among EMA, FDA, and PMDA
- 534 OD: The Promise of Digital Health Tools in Delivering Value to Patients and Health Systems
- 535 OD: The Ultimate Collaboration: Diversity, Inclusion and Professional Development
    - 542 OD: Basics of Healthcare Reform for Lifesciences Professionals